Figure 2.

Treatment duration. A swimmer plot of the treatment duration in patients with advanced TRK fusion-positive thyroid carcinoma treated with larotrectinib. ^||Three PDTCs, two in the anaplastic group and one in the papillary group. ATC, anaplastic thyroid carcinoma; FTC, follicular thyroid carcinoma; PDTC, poorly differentiated thyroid carcinoma; PTC, papillary thyroid carcinoma; TRK, tropomyosin receptor kinase. A full colour version of this figure is available at https://doi.org/10.1530/EJE-21-1259.